skip to content
 

Dr Maria Joáo Correia Pinto Carvalho de Matos

Publications 

75. Coumarin versus chromone monoamine oxidase B inhibitors: Quo vadis? (Fonseca A, Reis J, Silva TB, Matos MJ, Bagetta D, Ortuso F, Alcaro S, Uriarte E, Borges F*) J Med Chem 2017, accepted.

74. MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis, in vitro study and docking calculations (Delogu GL*, Pintus F, May L, Matos MJ, Vilar S, Munín J, Fontenla JA, Hripcsak G, Borges F, Viña D) MedChemComm 2017, accepted. Doi: 10.1039/C7MD00311K.

73. In silico genotoxicity of coumarins: application of Phenol-Explorer food database to functional food science (Guardado Yordi E*, Matos MJ, Pérez Martínez A, Tornes AC, Santana L, Molina E, Uriarte E) RSC Food & Function 2017, accepted. Doi: 10.1039/C7FO00402H.

72. Coumarins and adenosine receptors: new perceptions in structure-affinity relationships (Fonseca A, Matos MJ, Vilar S, Kachler S, Klotz K-N, Uriarte E, Borges F*) Chem Biol Drug Des 2017, accepted. doi: 10.1111/cbdd.13075.

71. New insights into highly potent tyrosinase inhibitors based on 3-heteroarylcoumarins: anti-melanogenesis and antioxidant activities, and computational molecular modeling studies (Pintus F, Matos MJ*, Vilar S, Hripcsak G, Varela C, Uriarte E, Santana L, Borges F, Medda R, Di Petrillo A, Era B, Fais A) Bioorg Med Chem 2017, 25, 1687-1695 DOI: 10.1016/j.bmc.2017.01.037.

70. Synthesis, antioxidant and antichagasic properties of a selected series of hydroxy-3-arylcoumarins (Robledo-O´Ryan N, Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Moncada-Basualto M, Mura F, Lapier M, Maya JD, Olea-Azar C*) Bioorg Med Chem 2017, 25, 621-632 DOI: http://dx.doi.org/10.1016/j.bmc.2016.11.033.

69. Trends in therapeutic drug conjugates for bacterial diseases: a patent review (Cal PMSD, Matos MJ*, Bernardes GJL) Exp Opin Therap Pat 2017, 27(2), 179-189. DOI: 10.1080/13543776.2017.1259411.

68. Heterocyclic antioxidants in nature: coumarins (Matos MJ*, Vazquez-Rodriguez S, Fonseca A, Uriarte E, Santana L, Borges F) Curr Org Chem 2017, 21(4), 311-324. DOI: 10.2174/1385272820666161017170652.

67. Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents (Bernardim B, Cal PMSD, Matos MJ, Oliveira B, Martínez-Sáez N, Albuquerque I, Burtoloso A, Jiménez-Osés G, Bernardes GJL*) Nature Commun 2016, 7, 13128. DOI: 10.1038/ncomms13128.

66. Structural elucidation of a series of 6-methyl-3-carboxamidocoumarins (Fonseca A, Gaspar A, Matos MJ, Gomes LR, Low JN, Uriarte E, Borges F*) Magn Reson Chem 2016, 55(4), 373-378. DOI: 10.1002/mrc.4541.

65. 6-Methylcoumarin-N-(quinolin-6-yl)-3-carboxamide: crystal structure and Hirshfeld surface analysis (Gomes LR, Low JN,* Fonseca A, Matos MJ, Borges F) Acta Cryst E 2016, E72, 1121-1125. doi: 10.1107/S2056989016011026.

64. Evaluation of antioxidant and antitrypanosomal properties of a selected series of synthetic 3-carboxamidocoumarins (Muñoz A, Fonseca A, Matos MJ*, Uriarte E, Santana L, Borges F, Figueroa R, Olea-Azar C*) ChemistrySelect 2016, 1(15), 4957-4964. DOI: 10.1002/slct.201601336.

63. Crystal structures of three 6-substituted coumarin-3-carboxamide derivatives (Gomes LR, Low JN*, Fonseca A, Matos MJ, Borges F) Acta Cryst E 2016, E72, 926-932. doi.org/10.1107/S2056989016008665.

62. Exploring coumarin potentialities: development of new MAO-B inhibitors based on the 6-methyl-3-carboxamidocoumarin scaffold (Fonseca A, Matos MJ, Reis J, Duarte Y, Gutiérrez M, Santana L, Uriarte E, Borges F) RSC Adv 2016, 6, 49764-49768. doi: 10.1039/c6ra05262b.

61. 2-Phenylbenzofuran derivatives as butyrylcholinesterase inhibitors: synthesis, biological activity and molecular modeling (Delogu G, Matos MJ, Fanti M, Era B, Medda R, Pieroni E, Fais A*, Kumar A*, Pintus F) Bioorg Med Chem Lett 2016, 26, 2308-2313. doi: 10.1016/j.bmcl.2016.03.039.

60. Progress in the development of small molecules as new human A3 adenosine receptor ligands based on the 3-thiophenylcoumarin core (Matos MJ*, Vilar S, Kachler S, Vazquez-Rodriguez S, Varela C, Delogu G, Hripcsak G, Santana L, Uriarte E, Klotz KN, Borges F) MedChemComm 2016, 7, 845-852. doi: 10.1039/C5MD00573F.

59. Facing Chagas’ disease: trypanocidal properties of new coumarin-chalcone scaffolds (Vazquez-Rodriguez S*, Figueroa Guíñez R, Matos MJ, Olea-Azar C, Maya JD, Uriarte E, Santana L, Borges F) Med Chem 2016, 12(6), 537-543. doi: 10.2174/1573406412666160107111809.

58. 3-Amidocoumarins as potential multifunctional agents against neurodegenerative diseases (Matos MJ*, Rodríguez-Enríquez F, Borges F*, Santana L, Uriarte E, Estrada M, Rodríguez-Franco MI, Laguna R, Viña D*) ChemMedChem 2015, 10, 2071-2079. doi: 10.1002/cmdc.201500408. 

57. Design and discovery of tyrosinase inhibitors based on the coumarin scaffold (Matos MJ*, Varela C, Vilar S, Hripcsak G, Borges F, Santana L, Uriarte E, Fais A, Di Petrillo A, Pintus F, Era B) RSC Adv 2015, 5, 94227-94233. doi: 10.1039/C5RA14465E. 

56. Bioactive coumarins from marine sources: origin, structural features and pharmacological properties (Vazquez-Rodriguez S*, Matos MJ, Borges F, Uriarte E, Santana L) Curr Top Med Chem 2015, 15(17), 1755-1766. doi: 10.2174/1568026615666150427125916. 

55. Design, synthesis and antibacterial study of new potent and selective coumarin–chalcone derivatives for the treatment of tenacibaculosis (Vazquez-Rodriguez S*, Lama López R, Matos MJ, Armesto-Quintas G, Serra S, Uriarte E, Santana L, Borges F, Muñoz Crego A, Santos Y) Bioorg Med Chem 2015, 23(21), 7045-7052. doi: 10.1016/j.bmc.2015.09.028. 

54. Synthesis and pharmacological activities of non-flavonoid chromones: a patent review (from 2005-2015) (Matos MJ*, Vazquez-Rodriguez S, Uriarte E, Santana L, Borges F) Exp Opin Therap Pat 2015, 25(11), 1-20. doi: 10.1517/13543776.2015.1078790. 

53. Relationship between thermodynamic parameters and genotoxicity of bioactive phenolic compounds (Guardado Yordi E*, Matos MJ, Santana L, Uriarte E, Pérez Martínez A, Molina Pérez E) Bri Biomed Bull 2015, 3(3), 317-329. 

52. Natural coumarins: QSRT approaches regarding their genotoxicity (Guardado Yordi E*, Matos MJ, Santana L, Uriarte E, Abreu O, Molina Pérez E) Biol Chem Res 2015, 241-257.

51. Development of novel adenosine receptor ligands based on the 3-amidocoumarin scaffold (Matos MJ*, Vilar S, Kachler S, Celeiro M, Vazquez-Rodriguez S, Santana L, Uriarte E, Hripcsak G, Borges F, Klotz KN) Bioorg Chem 2015, 61, 1-6. doi: 10.1016/j.bioorg.2015.05.008. 

50. Study of coumarin-resveratrol hybrids as potent antioxidant compounds (Matos MJ*, Mura F, Vazquez-Rodriguez S, Borges F, Santana L, Uriarte E, Olea-Azar C*) Molecules 2015, 20, 3290-3308. doi: 10.3390/molecules20023290. 

49. Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives (Matos MJ*, Rodríguez-Enríquez F, Vilar S, Santana L, Uriarte E, Hripcsak G, Estrada M, Rodríguez-Franco MI, Viña D) Bioorg Med Chem Lett 2015, 25, 642-648. doi: 10.1016/j.bmcl.2014.12.001. 

48. Oxidative stress and neurodegenerative diseases: looking for a therapeutic solution inspired on benzopyran chemistry (Gaspar A, Milhazes N, Santana L, Uriarte E, Borges F, Matos MJ*) Curr Top Med Chem 2015, 15(5), 432-445. doi: 10.2174/1568026614666141229124141. 

47.The interest of antioxidants agents in parasitic diseases. The case study of coumarins (Figueroa-Guinez R, Matos MJ, Vazquez-Rodriguez S, Santana L, Uriarte E, Olea-Azar C*, Borges F, Diego Maya J) Curr Top Med Chem 2015, 15(9), 850-856. doi: 10.2174/1568026615666150220113155.

46. In silico clastogenic activity of dietary phenolic acids (Guardado Yordi E*, Matos MJ, Castro Pupo R, Santana L, Uriarte E, Molina Pérez E) LWT Food Sci Tech 2015, 61, 216-223. doi: 10.1016/j.lwt.2014.11.012. 

45. Potential pharmacological uses of chalcones: a patent review (from June 2011-2014) (Matos MJ*, Vazquez-Rodriguez S, Uriarte E, Santana L) Exp Opin Therap Pat 2015, 25(3), 351-366. doi: 10.1517/13543776.2014.995627. 

44. Insights into the interaction of novel coumarin derivatives with human A3 adenosine receptors (Matos MJ*, Vilar S, Kachler S, Fonseca A, Santana L, Uriarte E, Borges F, Tatonetti NP, Klotz KN) ChemMedChem 2014, 9, 2245-2253 (paper selected as back cover of the issue). doi: 10.1002/cmdc.201402205. 

43. Insights into functional and structural properties of 3-arylcoumarins as an interesting scaffold in MAO-B inhibition (Matos MJ*, Vilar S, García-Morales V, Tatonetti NP, Uriarte E, Santana L, Viña D) ChemMedChem 2014, 9, 1488-1500. doi: 10.1002/cmdc.201300533. 

42. Synthesis and electrochemical study of new 3-(hydroxyphenyl)benzo[f]coumarins (Matos MJ, Janeiro P, Santana L, Uriarte E, Oliveira-Brett AM*) J Electroanal Chem 2014, 726, 62-70. doi: 10.1016/j.jelechem.2014.05.003. 

41. Synthesis, pharmacological study and docking calculations of new benzo[f]coumarin derivatives as dual inhibitors of enzymatic systems involved in neurodegenerative diseases (Matos MJ*, Janeiro P, González Franco RM, Vilar S, Tatonetti NP, Santana L, Uriarte E, Borges F, Fontanela JA, Viña D) Fut Med Chem 2014, 6(4), 371-383. doi: 10.4155/fmc.14.9. 

40. Chromone: a valid scaffold in medicinal chemistry (Gaspar A, Matos MJ, Garrido J, Uriarte E, Borges F*) Chem Rev 2014, 114 (9), 4960-4992. doi: 10.1021/cr400265z. 

39. Synthesis and evaluation of antioxidant and trypanocidal properties of a selected series of coumarin derivatives (Figueroa Guíñez R, Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Olea-Azar C*, Maya JD) Fut Med Chem 2013, 5(16), 1911-1922. doi: 10.4155/fmc.13.147. 

38. Comparative study of the 3-phenylcoumarin scaffold: synthesis, X-ray structural analysis and semiempirical calculations of a selected series of compounds (Matos MJ*, Vilar S, Tatonetti NP, Santana L, Uriarte E) J Mol Struct 2013, 1050, 185-191. doi: 10.1016/j.molstruc.2013.07.037. 

37. Synthesis, electrochemical and biological studies on novel coumarin-chalcone hybrid compounds (Pérez-Cruz F, Vazquez-Rodriguez S*, Matos MJ, Herrera-Morales A, Villamena F, Das A, Gopalakrishnan B, Olea-Azar C, Santana L, Uriarte E) J Med Chem 2013, 56, 6136-6145. doi: 10.1021/jm400546y. 

36. QSAR and complex network recognition of miRNAs in stem cells (Molina E*, Uriarte E, Santana L, Matos MJ, Borges F) Curr Bioinf 2013, 8, 438-451. doi: 2212-392X/13. 

35. Synthesis and adenosine receptors binding affinities of a series of 3-arylcoumarins (Matos MJ*, Hogger V, Gaspar A, Kachler S, Borges F, Uriarte E, Santana L, Klotz KN) J Pharm Pharmacol 2013, 65, 1590-1597. doi: 10.1111/jphp.12135. 

34. (1S,2S,5S)-2-Methyl-3-oxo-5-(prop-1-en-2-yl)cyclohexane-1-carbonitrile (Rivadulla ML, Fall A, González M, Matos MJ*) Acta Cryst 2013, E69, o799. doi: 10.1107/S1600536813011197. 

33. [(2S,3aR,6aR)-5-Oxohexahydrofuro[3,2-b]furan-2-yl]methyl acetate (González M, Martínez A, Rivadulla ML, Matos MJ*) Acta Cryst 2013, E69, o772. doi: 10.1107/S1600536813010313. 

32. Synthesis of coumarin-chalcone hybrids and evaluation of their antioxidant and trypanocidal properties (Vazquez-Rodriguez S*, Figueroa-Guíñez R, Matos MJ, Santana L, Uriarte E, Lapier M, Maya JD, Olea-Azar C*) MedChemComm 2013, 4, 993-1000. doi: 10.1039/c3md00025g. 

31. MAO inhibitory activity of 2-arylbenzofurans versus 3-arylcoumarins: synthesis, in vitro study and docking calculations (Ferino G, Cadoni E, Matos MJ*, Quezada E, Uriarte E, Santana L, Vilar S, Tatonetti NP, Yáñez M, Viña D, Picciau C, Serra S, Delogu G*) ChemMedChem 2013, 8, 956-966. doi: 10.1002/cmdc.201300048. 

30. Remarkable antioxidant properties of a series of hydroxy-3-arylcoumarins (Matos MJ*, Pérez-Cruz F, Vazquez-Rodriguez S, Uriarte E, Santana L, Borges F, Olea-Azar C) Bioorg Med Chem 2013, 21, 3900-3906. doi: 10.1016/j.bmc.2013.04.015. 

29. Synthesis, NMR characterization, X-ray structural analysis and theoretical calculations of amide and ester derivatives of the coumarin scaffold (Matos MJ*, Uriarte E, Santana L, Vilar S) J Mol Struct 2013, 1041, 144-150. doi: 10.1016/j.molstruc.2013.03.014. 

28. Chalcone-based derivatives as new scaffolds for hA3 adenosine receptor antagonists (Vazquez-Rodriguez S*, Matos MJ, Santana L, Uriarte E, Borges F, Kachler S, Klotz KN) J Pharm Pharmacol 2013, 65, 697-703. doi: 10.1111/jphp.12028. 

27. Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study (Matos MJ*, Vilar S, Gonzalez-Franco RM, Uriarte E, Santana L, Friedman C, Tatonetti NP, Viña D, Fontenla JA) Eur J Med Chem 2013, 63, 151-161. doi: 10.1016/j.ejmech.2013.02.009. 

26. Synthesis and structure-activity relationships of novel amino/nitro substituted 3-arylcoumarins as antibacterial agents (Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Fuentes-Edfuf C, Santos Y, Muñoz-Crego A) Molecules 2013, 18, 1394-1404. doi: 10.3390/molecules18021394. 

25. New hydroxylated 3-arylcoumarins, synthesis and electrochemical study (Janeiro P, Matos MJ, Santana L, Uriarte E, Oliveira-Brett AM*) J Electroanal Chem 2013, 689, 243-251. doi: http://dx.doi.org/10.1016/j.jelechem.2012.10.020. 

24. Targeting adenosine receptors with coumarins: synthesis and binding activities of amide and carbamate derivatives (Matos MJ*, Gaspar A, Kachler S, Klotz KN, Borges F, Santana L, Uriarte E) J Pharm Pharmacol 2013, 65, 30-34. doi: 10.1111/j.2042-7158.2012.01571.x.

23. Focusing on new monoamine oxidase inhibitors: differently substituted coumarins as an interesting scaffold (Matos MJ, Viña D, Vazquez-Rodriguez S, Uriarte E, Santana L*) Curr Top Med Chem 2012, 12, 2210-2239. doi: 10.2174/156802612805220002. 

22. Monoamine oxidase inhibitors: ten years of docking studies (Ferino G*, Vilar S, Matos MJ, Uriarte E, Cadoni E) Curr Top Med Chem 2012, 12, 2145-2162. doi: 10.2174/156802612805220048. 

21. N-(2-Oxo-2H-chromen-3-yl)cyclohexanecarboxamide (Matos MJ*, Santana L, Uriarte E) Acta Cryst 2012, E68, o3447-o3448. doi: 10.1107/S1600536812047903. 

20. Improved synthesis of 3-(aminoaryl)coumarins (Matos MJ*, Gaspar A, Borges F, Uriarte E, Santana L) Org Prep Proc Int 2012, 44, 522-526. doi: 10.1080/00304948.2012.730937. 

19. 3-Phenylcoumarin (Matos MJ*, Santana L, Uriarte E) Acta Cryst 2012, E68, o2645. doi: 10.1107/S1600536812034277. 

18. Looking for new targets: simple coumarins as antibacterial agents (Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Fuentes-Edfuf C, Santos Y, Muñoz-Crego A) Med Chem 2012, 8, 1140-1145. doi: http://dx.doi.org/10.2174/157340612804075205. 

17. In search for new chemical entities as adenosine receptor ligands: development of agents based on benzo-γ-pyrone skeleton (Gaspar A, Reis J, Matos MJ, Uriarte E, Borges F*) Eur J Med Chem 2012, 54, 914-918. doi: 10.1016/j.ejmech.2012.05.033. 

16. Monoamino oxidase A: an interesting pharmacological target for the development of multi-target QSAR models (Molina E*, Sobarzo-Sánchez E, Speck-Planche A, Matos MJ*, Uriarte E, Santana L, Yáñez M, Orallo F) Mini Rev Med Chem 2012, 12, 947-958. doi: 10.2174/138955712802762383. 

15. 8-Substituted-3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation and docking studies (Viña D, Matos MJ*, Ferino G, Cadoni E, Laguna R, Borges F, Uriarte E, Santana L) ChemMedChem 2012, 7, 464-470 (According to the Thomson Reuters Web of Science, this Full Paper was among the top 10 most cited articles published by ChemMedChem in 2012). doi: 10.1002/cmdc.201100538. 

14. Tyrosine-like condensed derivatives as tyrosinase inhibitors (Matos MJ*, Santana L, Uriarte E, Serra S, Corda M, Fadda MB, Era B, Fais A) J Pharm Pharmacol 2012, 64, 742-746. doi: 10.1111/j.2042-7158.2012.01467.x. 

13. Structural alerts for predicting clastogenic activity of pro-oxidant flavonoid compounds: quantitative structure–activity relationship study (Guardado E*, Molina E, Matos MJ, Uriarte E) J Biomol Screen 2012, 17(2), 216-224. doi: 10.1177/1087057111421623. 

12. Hydroxycoumarins as selective MAO-B inhibitors (Serra S*, Ferino G, Matos MJ, Vázquez-Rodríguez S, Delogu G, Viña D, Cadoni E, Santana L, Uriarte E) Bioor Med Chem Lett 2012, 22, 258-261. doi: 10.1016/j.bmcl.2011.11.020. 

11. 3-Substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer´s disease (Viña D, Matos MJ*, Yáñez M, Santana L, Uriarte E) MedChemComm 2012, 3, 213-218 (Featured in the top 10% of the most highly cited articles published in the latest Impact Factor window 2011-2012). doi: 10.1039/c1md00221j. 

10. Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors (Matos MJ*, Terán C, Pérez-Castillo Y, Uriarte E, Santana L, Viña D*) J Med Chem 2011, 54, 7127-7137. doi: dx.doi.org/10.1021/jm200716y. 

9. MAO inhibitory activity modulation: 3-phenylcoumarins versus 3-benzoylcoumarins (Matos MJ, Vázquez-Rodriguez S, Uriarte E, Santana L, Viña D*) Bioorg Med Chem Lett 2011, 21, 4224-4227. doi: 10.1016/j.bmcl.2011.05.074. 

8. New halogenated phenylcoumarins as tyrosinase inhibitors (Matos MJ*, Santana L, Uriarte E, Delogu G, Corda M, Fadda MB, Era B, Fais A) Bioorg Med Chem Lett 2011, 21, 3342-3345. doi: 10.1016/j.bmcl.2011.04.012. 

7. Synthesis of 3-arylcoumarins via Suzuki-cross-coupling reactions of 3-chlorocoumarin (Matos MJ*, Vazquez-Rodriguez S, Borges F, Santana L, Uriarte E) Tetrahedron Lett 2011, 52, 1225-1227. doi: 10.1016/j.tetlet.2011.01.048. 

6. Regioselective synthesis of different bromo substituted 3-arylcoumarins (Matos MJ*, Delogu G, Podda G, Santana L, Uriarte E) Synthesis 2010, 16, 2763-2766. doi: 10.1055/s-0029-1218835. 

5. New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors (Matos MJ*, Viña D, Janeiro P, Borges F, Santana L, Uriarte E) Bioorg Med Chem Lett 2010, 20, 5157-5160. doi: 10.1016/j.bmcl.2010.07.013. 

4. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors (Matos MJ*, Viña D, Picciau C, Orallo F, Santana L, Uriarte E) Bioorg Med Chem Lett 2009, 19, 5053-5055. doi: 10.1016/j.bmcl.2009.07.039. 

3. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors (Matos MJ*, Viña D, Quezada E, Picciau C, Delogu G, Orallo F, Santana L, Uriarte E) Bioorg Med Chem Lett 2009, 19, 3268-3270. doi: 10.1016/j.bmcl.2009.04.085. 

2. Tyrosinase inhibitor activity of the coumarin-resveratrol hybrids (Fais A*, Corda M, Era B, Fadda MB, Matos MJ, Quezada E, Santana L, Picciau C, Podda G, Delogu G) Molecules 2009, 14, 2514-2520. doi: 10.3390/molecules14072514. 

1. Synthesis of regio-isomeric functionalized benzodifurans and angelicins (Quezada E, Delogu G*, Viña D, Podda G, Matos MJ, Picciau C) Helv Chim Acta 2009, 92, 1309-1314. doi: 10.1002/hlca.200800421. 

 

Research Group

Telephone number

01223 336698 (shared)

Email address

mm2147@cam.ac.uk